Mark S. Dennis

Overview

Best Publications

• Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

  Jagath R Junutula;Helga Raab;Suzanna Clark;Sunil Bhakta

  1433
  Citations

• Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins

  Mark S. Dennis;Min Zhang;Y. Gloria Meng;Miryam Kadkhodayan

  1148
  Citations

• Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target

  Y. Joy Yu;Yin Zhang;Margaret Kenrick;Kwame Hoyte

  755
  Citations

• High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold.

  Chingwei V Lee;Wei-Ching Liang;Mark S Dennis;Charles Eigenbrot

  628
  Citations

• Binding polypeptides with diversified and consensus vh/vl hypervariable sequences

  Mark S. Dennis;Wei-Ching Liang;Yan Wu

  457
  Citations

• Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms: evidence for a family of platelet-aggregation inhibitors.

  Mark S. Dennis;William J. Henzel;Robert M. Pitti;Michael T. Lipari

  416
  Citations

• Imaging Tumors with an Albumin-Binding Fab, a Novel Tumor-Targeting Agent

  Mark S. Dennis;Hongkui Jin;Debra Dugger;Renhui Yang

  357
  Citations

• Rubber elongation factor from Hevea brasiliensis. Identification, characterization, and role in rubber biosynthesis.

  M S Dennis;D R Light

  350
  Citations

• Solution structure of kistrin, a potent platelet aggregation inhibitor and GP IIb-IIIa antagonist

  Marc Adler;Robert A. Lazarus;Mark S. Dennis;Gerhard Wagner

  347
  Citations

• Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates

  Y. Joy Yu;Jasvinder K. Atwal;Yin Zhang;Raymond K. Tong

  336
  Citations

• Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants

  Nga Bien-Ly;Y. Joy Yu;Daniela Bumbaca;Justin Elstrott

  324
  Citations

• Therapeutic potential of an anti-CD79b antibody–drug conjugate, anti–CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma

  David Dornan;Fiona Bennett;Yvonne Chen;Mark Dennis

  317
  Citations

• Peptide exosite inhibitors of factor VIIa as anticoagulants

  Mark S. Dennis;Charles Eigenbrot;Nicholas J. Skelton;Mark H. Ultsch

  295
  Citations

• Methods and compositions for prolonging elimination half-times of bioactive compounds

  Warren L. Delano;Mark S. Dennis;Henry B. Lowman

  293
  Citations

• Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

  Mark Merchant;Xiaolei Ma;Henry R. Maun;Zhong Zheng

  267
  Citations

• Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice.

  Megan Lo;Hok Seon Kim;Raymond K. Tong;Travis W. Bainbridge

  261
  Citations

• Serum albumin binding peptides for tumor targeting

  Mark S. Dennis;Henry B. Lowman;Warren L. Delano

  261
  Citations

• Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies

  Liping L. Sun;Diego Ellerman;Mary Mathieu;Maria Hristopoulos

  254
  Citations

• Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies

  Y. Joy Yu Zuchero;Xiaocheng Chen;Nga Bien-Ly;Daniela Bumbaca

  249
  Citations

• Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier

  Jessica A. Couch;Y. Joy Yu;Yin Zhang;Jacqueline M. Tarrant

  241
  Citations